Other publications - Alexander Lee

2020

  • LyRIC indeterminate response and confirmed immune-mediated pseudoprogression of refractory diffuse large B cell lymphoma following polatuzumab-based salvage chemoimmunotherapy Lee ATJ, Attygale AD, Iyengar S et al. B J Haem; May 2020
  • Pazopanib as a choice for solitary fibrous tumour. Lee ATJ, Benson C. Lancet Oncol 2020 Mar;21(3):332-333. doi: 10.1016/S1470-2045(20)30018-8

2019

  • Ewing-like sarcomas: new molecular diagnoses in need of optimised treatment approaches Lee ATJ, Huang PH, Jones RL. Indian J Med Res. 2019 Dec; 150(6): 521–523.
  • Negative phase III trials announce the need for biomarkers in sarcoma Lee ATJ, Huang PH, Jones RL. Eur J Cancer 2019. 123; 81-82. doi: 10.1016/j.ejca.2019.08.035
  • Pazopanib in advanced soft tissue sarcomas. Lee ATJ, Jones RL, Huang PH. Sig Trans Targ Ther 2019; 4: 16. doi: 10.1038/s41392-019-0049-6
  • The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. Lee ATJ, Chew W, Wilding CM et al. Sci Rep 2019; 9,14602. doi:10.1038/s41598-019-50888-5

2018

  • Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Chew W, Benson C, Thway K et al. Medical Oncology 2018. 35(11):138. doi: 10.1007/s12032-018-1192-6
  • Clinical and molecular spectrum of liposarcoma. Lee ATJ, Thway K, Huang PH, Jones RL. J Clin Oncol 2018. 36(2): 151-159. doi: 10.1200/JCO.2017.74.9598
  • Olaratumab in soft tissue sarcoma – Current status and future perspectives. Antoniou G, Lee ATJ, Huang P, Jones RL. Eur J Cancer 2018; 92:33-39. doi: 10.1016/j.ejca.2017.12.026
  • 2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma Frezza AM, Lee ATJ, Nizri E et al. ESMO Open 2018;3:e000390.doi:10.1136/esmoopen-2018-000390

2015 - 2017

  • Progress and Impact of clinical phosphoproteomics on precision oncology Lima N*, Lee A*, Huang P. Translational Cancer Research 2017;6(Suppl 6):S1108-S1114. doi: 10.21037/tcr.2017.07.05
  • Phase III soft tissue sarcoma trials: Success or Failure? Lee APollack S, Huang P & Jones R. Current Treatment Options in Oncology 2017; 18(3):19. Doi: 10.1007/s11864-017-0457-1
  • Novel therapeutic approaches in chondrosarcoma Polychronidou G, Karavasilis V, Pollack S, Huang P, Lee A, Jones R. Future Oncology. 2017 Mar; 13(7). doi: 10.2217/fon-2016-0226
  • Immunotherapy for Soft Tissue Sarcoma - Tomorrow is Only a Day Away Lee A, Huang P, DeMatteo R, & Pollack S.  ASCO Educational Book 2016;35;281-90. doi: 10.14694/EDBK_157439
  • Drug repositioning in sarcomas and other rare tumours Lee A, Huang P, Pollack S, Jones R. EBioMedicine (2016). doi:10.1016/j.ebiom.2016.03.021
  • Prognostic score for patients with advanced melanoma treated with ipilimumab Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, Larkin J
  • European Journal of Cancer 2015. 51, 2785–91. doi: 10.1016/j.ejca.2015.09.007

Last updated: January 2023